Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

SHMT2-RES Citations (1)

Originally described in: SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance.
Kim D, Fiske BP, Birsoy K, Freinkman E, Kami K, Possemato RL, Chudnovsky Y, Pacold ME, Chen WW, Cantor JR, Shelton LM, Gui DY, Kwon M, Ramkissoon SH, Ligon KL, Kang SW, Snuderl M, Vander Heiden MG, Sabatini DM Nature. 2015 Apr 16;520(7547):363-7. doi: 10.1038/nature14363. Epub 2015 Apr 8. PubMed Journal

Articles Citing SHMT2-RES

Articles
Metformin Is a Pyridoxal-5'-phosphate (PLP)-Competitive Inhibitor of SHMT2. Tramonti A, Cuyas E, Encinar JA, Pietzke M, Paone A, Verdura S, Arbusa A, Martin-Castillo B, Giardina G, Joven J, Vazquez A, Contestabile R, Cutruzzola F, Menendez JA. Cancers (Basel). 2021 Aug 9;13(16). pii: cancers13164009. doi: 10.3390/cancers13164009. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.